# The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

> **NCT05762458** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** Ammoxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05762458
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-28
- **Primary completion:** 2024-05-15
- **Final completion:** 2024-10-15
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05762458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05762458, "The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05762458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*